Nexalin Technology, Inc. (NXL)

NASDAQ: NXL · IEX Real-Time Price · USD
0.312
-0.020 (-6.02%)
Feb 27, 2024, 9:30 AM EST - Market open
-6.02%
Market Cap 2.27M
Revenue (ttm) 128,637
Net Income (ttm) -4.60M
Shares Out 7.29M
EPS (ttm) -0.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,122
Open 0.312
Previous Close 0.332
Day's Range 0.312 - 0.341
52-Week Range 0.253 - 1.140
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Mar 25, 2024

About NXL

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. In addition, it designs and develops Generation 2 and Generation 3, a medica... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Sep 16, 2022
Employees 6
Stock Exchange NASDAQ
Ticker Symbol NXL
Full Company Profile

Financial Performance

In 2022, NXL's revenue was $1.32 million, an increase of 817.20% compared to the previous year's $144,065. Losses were -$1.70 million, -72.07% less than in 2021.

Financial Statements

News

Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device

Company's International Reach Expanding with Latest Regulatory Approval Company's International Reach Expanding with Latest Regulatory Approval

19 days ago - GlobeNewsWire

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System

HOUSTON, TX, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO) has...

5 weeks ago - GlobeNewsWire

Nexalin Technology Unveils Next-Generation HALO™ Clarity

A new neurostimulation device to combat the growing global mental health epidemic Designed for drug-free treatment of mental health conditions from the privacy of one's home with virtual monitoring by...

6 weeks ago - GlobeNewsWire

Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression

Results published in General Psychiatry, a leading peer-reviewed journal Results published in General Psychiatry, a leading peer-reviewed journal

2 months ago - GlobeNewsWire

Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter

HOUSTON, TEXAS, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the formation of a Military & Government Advisory Board ( ...

4 months ago - GlobeNewsWire

Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin's Neurostimulation Device to Penetrate Deep Brain Structures

Study reveals that Nexalin's non-invasive, deep frequency stimulation medical device can directly stimulate the deep intracranial nuclei, an area of the brain frequently associated with trauma and men...

4 months ago - GlobeNewsWire

Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms

HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today provided an update on the growing body of clinical data supporting the poten...

7 months ago - GlobeNewsWire

Nexalin's CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time

HOUSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that its Chief Executive Officer, Mark White, will be participatin...

7 months ago - GlobeNewsWire

Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies

HOUSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the formation of a new division, to be called “Nexalin America,” a...

7 months ago - GlobeNewsWire

Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury

New data in traumatic brain injury (TBI) builds on prior study in insomnia, which has been shown to have high correlation with TBI New data in traumatic brain injury (TBI) builds on prior study in ins...

8 months ago - GlobeNewsWire

Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin's tACS Devices in the Asia Pacific Region

Wider Come to fund and conduct a total of four clinical trials, spanning insomnia, depression and other indications Wider Come to fund and conduct a total of four clinical trials, spanning insomnia, d...

9 months ago - GlobeNewsWire

Nexalin Technology Provides 2022 Year-End Business Update

HOUSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today provided a business update for the year ended December 31, 2022.

1 year ago - GlobeNewsWire

Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory

HOUSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the appointment of Michael Nketiah as Senior Vice President of Qu...

1 year ago - GlobeNewsWire

Nexalin Technology CEO Provides Letter to Shareholders

HOUSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today provided the following business update and letter to shareholders from its ...

1 year ago - GlobeNewsWire

Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety Disorder

The Second Xiangya Hospital of Central South University, China, reports positive patient results, including disappearance of all somatic anxiety symptoms and improved quality of sleep

1 year ago - GlobeNewsWire

Nexalin Technology, Inc. Announces Closing of $9.6 Million Initial Public Offering

HOUSTON, TEXAS, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) today announced the closing of its previously announced initial public offering of 2,315,000 un...

1 year ago - GlobeNewsWire

Nexalin Technology, Inc. Announces Pricing of $9.6 Million Initial Public Offering

HOUSTON, TEXAS, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) today announced the pricing of its initial public offering of 2,315,000 units consisting of  2,...

1 year ago - GlobeNewsWire